Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Durham-based Atsena Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for ATSN-201, its gene therapy product for the ...

Tourmaline Bio is well-funded, with cash runway into 2H 2027, minimizing near-term dilution risk for investors. Click here to ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a ...

Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and ...

Swiss pharma giant Roche is investing $280 million to build a new biopharma manufacturing facility in Shanghai, as it doubles ...

The company discontinued development last month of its most mature asset, RLYB212, following disappointing mid-stage ...

With growing uncertainty in the US, Chinese companies are swooping in to present themselves as stable, open partners to the ...

IN BRIEFUS Patent Office granted Active Biotech's patent application for laquinimod in eye disorders (January 28)Active Biotech announced that the first patient was enrolled in the European ...